Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Peking University Cancer Hospital & Institute

2 clinical trials · 2 recruiting · OTHER

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Peking University Cancer Hospital & Institute

RECRUITINGPhase 2NCT05512481

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.

Sponsor: Peking University Cancer Hospital & InstituteEnrolling: 601 location
MelanomaAcral MelanomaTemozolomide+4
RECRUITINGPhase 2NCT06869213

A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the...

This study is a prospective, observational clinical study. In this study, 30 patients with resectable locally advanced esophageal squamous carcinoma will be prospectively enrolled...

Sponsor: Peking University Cancer Hospital & InstituteEnrolling: 301 location
Esophageal Cancer (EsC)